sofosbuvir has been researched along with abt-333 in 44 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 35 (79.55) | 24.3611 |
2020's | 9 (20.45) | 2.80 |
Authors | Studies |
---|---|
Dadej, A; Jelińska, A; Muszalska, I; Sobczak, A; Tomczak, S; Zając, M | 1 |
Frakolaki, E; Giannakopoulou, E; Kelly, JM; Mikros, E; Myrianthopoulos, V; Pardali, V; Siozos, V; Taylor, MC; Vassilaki, N; Zoidis, G | 1 |
Hartmann, MD; Heim, C; Hernandez Alvarez, B; Maiwald, S | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E | 1 |
Cornberg, M; Höner zu Siederdissen, C | 1 |
Beinhardt, S; Ferenci, P; Hofer, H; Peck-Radosavljevic, M | 1 |
Colombo, M | 1 |
Halász, T; Horváth, G; Hunyady, B; Makara, M | 1 |
Bailly, F; Pradat, P; Virlogeux, V; Zoulim, F | 1 |
Buti, M; Esteban, R; Riveiro-Barciela, M | 1 |
Awni, WM; Cohen, D; Ding, B; Dutta, S; King, JR; Menon, RM; Podsadecki, TJ | 1 |
Asselah, T; Boyer, N; Marcellin, P; Martinot-Peignoux, M; Saadoun, D | 1 |
Johnson, S; Marx, SE; Misurski, D; Parisé, H; Saab, S; Sanchez Gonzalez, Y; Virabhak, S; Wang, A | 1 |
Berry, K; Beste, LA; Chang, MF; Green, PK; Ioannou, GN; Lowy, E; Su, F; Tsui, JI | 1 |
Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA | 1 |
Bryce, CL; Chidi, AP; Donohue, JM; Fine, MJ; Landsittel, DP; Myaskovsky, L; Rogal, SS; Smith, KJ; Switzer, GE; Tsung, A | 1 |
Gonzalez, YS; Johnson, S; Juday, T; Misurski, D; Parisé, H; Saab, S; Virabhak, S; Wang, A | 1 |
De Weggheleire, A; Dorlo, TP; Francque, S; Lynen, L; Meessen, B; Newton, PN; Pouget, C; Ravinetto, R; Sokkab, A; Tabernero, P | 1 |
Ashimkhanova, A; Kaliaskarova, K; Yesmembetov, K | 1 |
Aichelburg, MC; Bucsics, T; Ferenci, P; Grabmeier-Pfistershammer, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Scheiner, B; Schwabl, P; Steiner, S; Trauner, M | 1 |
Albillos, A; Ampuero, J; Arenas, J; Bañares, R; Calleja, JL; Crespo, J; Diago, M; Fernandez, I; García-Eliz, M; García-Samaniego, J; Gea, F; Jorquera, F; Lens, S; Llaneras, J; Llerena, S; Mariño, Z; Morillas, RM; Muñoz, R; Navascues, CA; Pascasio, JM; Perelló, C; Rincón, D; Rodriguez, CF; Ruiz-Antorán, B; Sacristán, B; Serra, MA; Simon, MA; Torras, X; Turnes, J | 1 |
Abou-Samra, AB; Butt, AA; Simon, TG; Yan, P | 1 |
Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Yang, JF; Yeh, ML; Yu, ML | 1 |
Agrati, C; Ammassari, A; Antinori, A; Bellagamba, R; Fabbri, G; Libertone, R; Lupi, F; Mastrorosa, I; Notari, S; Tempestilli, M; Timelli, L; Zaccarelli, M | 1 |
Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Pinna, SM | 1 |
Borba, HHL; Ferreira, VL; Leonart, LP; Pontarolo, R; Tonin, FS | 1 |
Cerban, R; Ester, C; Gheorghe, C; Gheorghe, L; Iacob, R; Iacob, S; Pietrareanu, C; Popescu, I | 1 |
Andersen, ES; Bukh, J; Christensen, PB; Fahnøe, U; Gerstoft, J; Kjær, MS; Laursen, AL; Mössner, B; Pedersen, MS; Røge, BT; Schønning, K; Sølund, C; Weis, N | 1 |
Abdel-Razek, W; Waked, I | 1 |
Borrego, P; Briz, V; Ezeonwumelu, IJ; Marcelino, R; Marinho, RT; Moranguinho, I; Palladino, C; Serejo, F; Taveira, N; Velosa, JF | 1 |
Eibl, MM; Müller, CJ; Wolf, HM | 1 |
Adamek, B; Baka-Ćwierz, B; Belica-Wdowik, T; Berak, H; Białkowska-Warzecha, J; Buczyńska, I; Citko, J; Czauż-Andrzejuk, A; Deroń, Z; Dobracki, W; Dybowska, D; Flisiak, R; Garlicki, A; Gietka, A; Halota, W; Horban, A; Janczewska, E; Jaroszewicz, J; Laurans, Ł; Lorenc, B; Mazur, W; Piekarska, A; Simon, K; Sitko, M; Socha, Ł; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Wawrzynowicz-Syczewska, M; Zarębska-Michaluk, D | 1 |
Abunimeh, M; Bennett, M; Cohen, DE; Cohen, E; Everson, G; Phillips, RW; Pilot-Matias, T; Poordad, F; Reindollar, RW; Sepe, TE; Siddique, A; Sullivan, JG; Younes, Z | 1 |
Amador, J; Di Bisceglie, AM; Evon, DM; Fried, MW; Golin, CE; Lim, JK; Lok, AS; Nelson, DR; Rajender Reddy, K; Reau, N; Reeve, BB; Sarkar, S; Serper, M; Sterling, RK; Stewart, PW | 1 |
Berg, T; Boeker, KHW; Buggisch, P; C-Registry, GH; Günther, R; Hinrichsen, H; Klinker, H; Manns, MP; Mauss, S; Müller, T; Serfert, Y; Wiegand, J; Zeuzem, S | 1 |
Cescon, M; De Pace, V; Galli, S; Maggi, F; Morelli, MC; Pistello, M; Ravaioli, M; Re, MC; Vero, V | 1 |
Aghayeva, S; Asiller, ÖÖ; Balkan, A; Çalışkan Kartal, A; Demir, M; Erarslan, E; Gülşen, MT; Güner, R; Köksal, I; Örmeci, N; Sezgin, O; Yaraş, S | 1 |
Bajis, S; Dore, GJ; Martinello, M | 1 |
Blackard, JT; Celentano, DD; Jamieson, DJ; King, CC; Klein, RS; Kong, L; Lin, D; Mayer, KH; Ngwaga, T; Schoborg, C; Sobel, JD; Tavis, JE; Taylor, LE | 1 |
Fedorchenko, SV; Klimenko, Z; Martynovych, T; Solianyk, I | 1 |
Darling, JM; Di Bisceglie, A; Dong, M; Evon, DM; Fishbein, DA; Fried, MW; Hinestrosa, F; Horne, PM; Khalili, M; Kixmiller, S; Lok, AS; Michael, L; Moon, JS; Morelli, G; Muir, AJ; Nelson, DR; Pearlman, B; Peter, J; Rajender Reddy, K; Segal, JB; Sherman, KE; Shiffman, ML; Sloan, A; Stewart, PW; Sulkowski, MS; Vainorius, M; Wadsworth, S | 1 |
Al-Zaydi, KM; Aljuaid, A; Allahyani, M; Almaghrabi, S; Almehmadi, M; Alshabrmi, FM; Baammi, S; Baothman, BK; Izmirly, AM; Salam, A; Shahab, M | 1 |
Jagannath, DK; Lakshminarasimhan, A; Malik, M; Mishra, RK; Vijayan, P | 1 |
10 review(s) available for sofosbuvir and abt-333
Article | Year |
---|---|
Hepatitis C - New drugs and treatment prospects.
Topics: Animals; Antiviral Agents; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Hepatitis C; Humans; Molecular Structure; Molecular Targeted Therapy; Protease Inhibitors | 2019 |
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
[All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Combinations; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cholestasis, Intrahepatic; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2015 |
Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
Topics: 2-Naphthylamine; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil | 2015 |
[New era in the treatment of chronic hepatitis C - novel direct acting antivirals].
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferons; Isoquinolines; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Nucleic Acid Synthesis Inhibitors; Proline; Protease Inhibitors; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins; Virus Replication | 2015 |
Management of direct-acting antiviral agent failures.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Failure; Uracil; Uridine Monophosphate; Valine | 2015 |
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins | 2016 |
Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2018 |
Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzofurans; Carbamates; Drug Therapy, Combination; Global Health; Health Care Costs; Hepatitis C, Chronic; Humans; Imidazoles; Proline; Pyrrolidines; Sofosbuvir; Sulfonamides; Uracil; Valine; World Health Organization | 2020 |
4 trial(s) available for sofosbuvir and abt-333
Article | Year |
---|---|
Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2016 |
Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
Topics: 2-Naphthylamine; Adult; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2019 |
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
Topics: 2-Naphthylamine; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine; Young Adult | 2021 |
30 other study(ies) available for sofosbuvir and abt-333
Article | Year |
---|---|
Scaffold hybridization strategy towards potent hydroxamate-based inhibitors of
Topics: | 2019 |
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
Topics: | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2015 |
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Models, Econometric; Proline; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2016 |
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Department of Veterans Affairs; Uracil; Uridine Monophosphate; Valine | 2016 |
Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Black or African American; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2016 |
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Combinations; Female; Fluorenes; Health Services Accessibility; Hepacivirus; Hepatitis C; HIV Protease Inhibitors; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Markov Chains; Medicaid; Middle Aged; Proline; Ritonavir; Severity of Illness Index; Sofosbuvir; Sulfonamides; United States; Uracil; Uridine Monophosphate; Valine | 2016 |
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; United States; Uracil; Valine | 2016 |
Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Industry; Drug Therapy, Combination; Fees, Pharmaceutical; Fluorenes; Health Services Accessibility; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Public Health; Pyrrolidines; Quality Assurance, Health Care; Quality Control; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2016 |
First Case in Kazakhstan of Successful Therapy With 2 Consecutive Direct-Acting Antiviral Regimens in a Patient with Hepatitis C Virus-Induced Decompensated Liver Cirrhosis on a Liver Transplant Wait List.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Kazakhstan; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Medication Adherence; Proline; Recurrence; Retreatment; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine; Waiting Lists | 2016 |
Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.
Topics: 2-Naphthylamine; Adult; AIDS-Related Opportunistic Infections; Anilides; Anti-HIV Agents; Antiviral Agents; Austria; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; HIV Seropositivity; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2017 |
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Neoplasm Recurrence, Local; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine; Young Adult | 2017 |
Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Propensity Score; Proportional Hazards Models; Ritonavir; Sofosbuvir; Sulfonamides; Survival Rate; Sustained Virologic Response; Uracil; Valine | 2017 |
The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Glucose; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Insulin Resistance; Insulin-Secreting Cells; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2017 |
Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world.
Topics: 2-Naphthylamine; Anilides; Anti-Retroviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Uridine Monophosphate; Valine | 2018 |
Editorial: is sofosbuvir-based therapy suitable for patients with advanced chronic kidney disease?
Topics: 2-Naphthylamine; Anilides; Benzimidazoles; Carbamates; Cyclopropanes; Fluorenes; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Renal Insufficiency, Chronic; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Epidemic history of hepatitis C virus genotypes and subtypes in Portugal.
Topics: 2-Naphthylamine; Adult; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Molecular Epidemiology; Polymorphism, Genetic; Portugal; Sofosbuvir; Sulfonamides; Uracil; Viral Nonstructural Proteins | 2018 |
Oral direct-acting antiviral therapy for hepatitis C virus infection in X-linked agammaglobulinemia.
Topics: 2-Naphthylamine; Administration, Oral; Adult; Agammaglobulinemia; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genetic Diseases, X-Linked; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunoglobulin G; Immunoglobulins, Intravenous; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Pyrrolidines; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2019 |
The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Poland; Proline; Protease Inhibitors; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Uridine Monophosphate; Valine; Young Adult | 2018 |
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Patient Reported Outcome Measures; Proline; Prospective Studies; Quinoxalines; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2019 |
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Fluorenes; Germany; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Hypertension; Imidazoles; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Pleural Effusion; Proline; Pyrrolidines; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; RNA, Viral; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine | 2019 |
Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
Topics: 2-Naphthylamine; Antiviral Agents; Biomarkers, Pharmacological; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil | 2019 |
Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Azerbaijan; Cyclopropanes; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Turkey; Uracil; Valine | 2020 |
Diversity of the hepatitis C virus NS5B gene during HIV co-infection.
Topics: 2-Naphthylamine; Adult; AIDS-Related Opportunistic Infections; Amino Acid Sequence; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Drug Resistance, Viral; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; HIV; Humans; Phylogeny; RNA-Dependent RNA Polymerase; RNA, Viral; Sofosbuvir; Sulfonamides; Uracil; Viral Nonstructural Proteins | 2020 |
Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Mutation; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Viral Nonstructural Proteins | 2021 |
Structural Homology-Based Drug Repurposing Approach for Targeting NSP12 SARS-CoV-2.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Drug Repositioning; Humans; Molecular Docking Simulation; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sofosbuvir | 2022 |
Sofosbuvir and its tri-phosphate metabolite inhibit the RNA-dependent RNA polymerase activity of non-structural protein 5 from the Kyasanur forest disease virus.
Topics: Animals; Encephalitis Viruses, Tick-Borne; Haplorhini; Humans; India; Kyasanur Forest Disease; Phosphates; RNA-Dependent RNA Polymerase; Sofosbuvir; Viral Nonstructural Proteins | 2023 |